"The QMA gave us something most clinical-stage companies lack entirely: a quantitative, competitor-calibrated picture of exactly where the brand stood and exactly what to do next."
Case Study
Mapping Every Digital Blind Spot for a Clinical-Stage Pharma Brand
THEIR STORY
Strong Science. A Decision to Get the Data First.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company developing novel peptide-based therapies for patients with gastrointestinal conditions and blood disorders, with multiple programs advancing toward pivotal clinical milestones.
Before commercialization, the competitive digital landscape shapes how investors, analysts, and the clinical community perceive a brand. Leadership understood that the question wasn't whether to build digital presence, but where to start, how much to invest, and what the competitive environment actually looked like with data behind it.
Rather than committing to a strategy based on assumptions, Protagonist commissioned Arcalea to deliver a quantitative picture of where the brand stood today and what it would take to build meaningful market presence before the commercial window opened.
The Challenge
No Baseline. No Benchmarks. No Roadmap.
Protagonist had no external view of where the brand stood in the digital landscape. The company knew it had a compelling scientific story, but lacked any quantitative understanding of how that story was being received, discovered, or compared online relative to competitors at similar stages.
Before committing to content, paid media, or SEO, three questions needed real answers grounded in data: How aware is the relevant market of this brand today? How does the digital footprint compare to peers further along the development path? And which investments will move the needle most in this specific therapeutic area?
Investing without that clarity risked spending in the wrong places at the wrong time. The QMA was commissioned to answer all three questions definitively, before a dollar of digital spend was committed.
Results
Key Findings Across the Digital Stack
Across 17 dimensions, benchmarked against 4 direct competitors, the QMA delivered a precise, quantitative picture of where the brand stood and what the path forward looked like.
Surveying 664+ nationally representative respondents at 99% statistical confidence, the study delivered a quantified brand awareness baseline across the competitive set. At the clinical stage, awareness reflects development trajectory rather than market performance: the value was in knowing the precise starting point and what investment it would take to build recognition ahead of commercialization.
Information aggregators dominated the industry search landscape, but the analysis identified a clear content-driven path forward. Asset-specific competitor sites had already demonstrated that clinical-stage brands could capture meaningful organic share through targeted content strategy. The QMA mapped the specific query clusters, content architecture, and domain structure that would be most effective for this category.
The technical audit assessed domain configuration, site architecture, and crawl efficiency, ranking every finding by impact and sequencing remediation to preserve what was working. Protagonist held a genuine competitive advantage in site performance — the fastest desktop and mobile load times in the set — and every infrastructure recommendation was built around protecting that edge while expanding content reach.